Literature DB >> 11019976

Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors.

A Baurand1, A Eckly, N Bari, C Léon, B Hechler, J P Cazenave, C Gachet.   

Abstract

Platelets activated by ADP become refractory to restimulation, but the mechanism of this process is not well understood. A normal platelet response to ADP requires coactivation of the P2Y(1) receptor responsible for shape change and the P2cyc receptor, responsible for completion and amplification of the response. The aim of the present study was to characterize the desensitization of platelets to ADP and to determine whether or not these two receptors are desensitized simultaneously through identical pathways when platelets become refractory to ADP. It was found that full inhibition of platelet aggregation in response to restimulation by ADP required the presence of ADP in the medium or use of a high concentration (1 mM) of its non-hydrolysable analogue ADPbetaS. Platelets incubated for 1 h at 37 degrees C with 1 mM ADPbetaS and resuspended in Tyrode's buffer containing apyrase displayed a stable refractory state characterized by the inability to aggregate or change shape in response to ADP. ADPbetaS treated platelets loaded with fura-2/AM showed complete blockade of the calcium signal in response to ADP, whereas the capacity of ADP to inhibit PGE1 stimulated cAMP accumulation in these platelets was only diminished. Consequently, serotonin was able to promote ADP induced aggregation through activation of the Gq coupled 5HT(2A) receptor while adrenaline had no such effect. These results suggested that the refractory state of ADPbetaS treated platelets was entirely due to desensitization of the P2Y(1) receptor, the P2cyc receptor remaining functional. Binding studies were performed to determine whether the P2Y(1) and/or P2cyc binding sites were modified in refractory platelets. Using selective P2Y(1) and P2cyc antagonists (A3P5P and AR-C66096 respectively), we could demonstrate that the decrease in [33P]2MeSADP binding sites on refractory platelets corresponded to disappearance of the P2Y(1) sites with no change in the number of P2cyc sites, suggesting internalization of the P2Y(1) receptor. This was confirmed by flow cytometric analysis of Jurkat cells expressing an epitope-tagged P2Y(1) receptor, where ADPbetaS treatment resulted in complete loss of the receptor from the cell surface. We conclude that the P2Y(1) and P2cyc receptors are differently regulated during platelet activation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11019976

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  30 in total

1.  Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonists.

Authors:  R Gnana Ravi; Hak Sung Kim; Jörg Servos; Herbert Zimmermann; Kyeong Lee; Savitri Maddileti; José L Boyer; T Kendall Harden; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2002-05-09       Impact factor: 7.446

2.  (N)-methanocarba-2MeSADP (MRS2365) is a subtype-specific agonist that induces rapid desensitization of the P2Y1 receptor of human platelets.

Authors:  D M Bourdon; S K Mahanty; K A Jacobson; J L Boyer; T K Harden
Journal:  J Thromb Haemost       Date:  2006-04       Impact factor: 5.824

Review 3.  P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cells.

Authors:  Christian Gachet
Journal:  Purinergic Signal       Date:  2012-04-11       Impact factor: 3.765

Review 4.  International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

Authors:  Maria P Abbracchio; Geoffrey Burnstock; Jean-Marie Boeynaems; Eric A Barnard; José L Boyer; Charles Kennedy; Gillian E Knight; Marta Fumagalli; Christian Gachet; Kenneth A Jacobson; Gary A Weisman
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

5.  Historical perspective on ADP-induced platelet activation.

Authors:  Marian A Packham; Margaret L Rand
Journal:  Purinergic Signal       Date:  2011-04-02       Impact factor: 3.765

6.  Quantification of recombinant and platelet P2Y(1) receptors utilizing a [(125)I]-labeled high-affinity antagonist 2-iodo-N(6)-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([(125)I]MRS2500).

Authors:  Philippe Ohlmann; Sonia de Castro; Garth G Brown; Christian Gachet; Kenneth A Jacobson; T Kendall Harden
Journal:  Pharmacol Res       Date:  2010-06-04       Impact factor: 7.658

7.  Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs.

Authors:  C J Foster; D M Prosser; J M Agans; Y Zhai; M D Smith; J E Lachowicz; F L Zhang; E Gustafson; F J Monsma; M T Wiekowski; S J Abbondanzo; D N Cook; M L Bayne; S A Lira; M S Chintala
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

8.  Platelet reactivity in sepsis syndrome: results from the PRESS study.

Authors:  Karolina Akinosoglou; Spyridoula Theodoraki; Ioanna Xanthopoulou; Angelos Perperis; Theologia Gkavogianni; Aikaterini Pistiki; Evangelos Giamarellos-Bourboulis; Charalambos A Gogos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-08-24       Impact factor: 3.267

9.  Subtype specific internalization of P2Y1 and P2Y2 receptors induced by novel adenosine 5'-O-(1-boranotriphosphate) derivatives.

Authors:  M E Tulapurkar; W Laubinger; V Nahum; B Fischer; G Reiser
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

10.  Desensitization of endothelial P2Y1 receptors by PKC-dependent mechanisms in pressurized rat small mesenteric arteries.

Authors:  R Rodríguez-Rodríguez; P Yarova; P Winter; K A Dora
Journal:  Br J Pharmacol       Date:  2009-10-20       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.